EMA Consults On Managing Serious Breaches Under EU Clinical Trials Regulation
Executive Summary
The European Medicines Agency has issued a draft guideline that explains how drug sponsors should report serious breaches under the upcoming EU Clinical Trials Regulation. The guideline contains a non-exhaustive list of what may or may not qualify as a serious breach.